[{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"ae6dde76-a9e2-4ffe-85b4-d60ff795f82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919292","created_at":"2021-01-18T19:17:11.532Z","updated_at":"2025-02-25T13:48:40.499Z","phase":"Phase 1/2","brief_title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","source_id_and_acronym":"NCT03919292","lead_sponsor":"Virginia Commonwealth University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-21"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"4e07ea78-21b2-4abe-9c7a-53c1c0d6fed9","acronym":"KAN-HER2 MRD","url":"https://clinicaltrials.gov/study/NCT05388149","created_at":"2022-05-24T12:54:32.375Z","updated_at":"2025-02-25T17:25:36.146Z","phase":"Phase 2","brief_title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","source_id_and_acronym":"NCT05388149 - KAN-HER2 MRD","lead_sponsor":"University Health Network, Toronto","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-01-31"},{"id":"257cca5a-c910-4b83-b699-e799dee41eab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101748","created_at":"2021-01-18T15:16:53.226Z","updated_at":"2025-02-25T13:52:17.471Z","phase":"Phase 1/2","brief_title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03101748","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-13"},{"id":"2b8a33cf-62f0-4cf9-ab2c-6563d734fd34","acronym":"","url":"https://clinicaltrials.gov/study/NCT05760612","created_at":"2023-03-08T17:01:51.251Z","updated_at":"2025-02-25T13:55:01.559Z","phase":"Phase 3","brief_title":"A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment with Trastuzumab Combined with Parezumab","source_id_and_acronym":"NCT05760612","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • HER-2 amplification + HR-positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • HER-2 amplification + HR-positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 02/16/2028","primary_completion_date":" 02/16/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-11-28"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"2b8e2f91-c4ad-4a30-bf4b-d41f2c7c9a84","acronym":"INSIGhT","url":"https://clinicaltrials.gov/study/NCT02977780","created_at":"2021-01-18T14:38:25.857Z","updated_at":"2025-02-25T14:36:55.862Z","phase":"Phase 2","brief_title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","source_id_and_acronym":"NCT02977780 - INSIGhT","lead_sponsor":"Patrick Wen, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-10-17"},{"id":"8d1ccb5b-f750-498e-b8e0-01cc46ef60cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919108","created_at":"2023-06-26T14:09:19.440Z","updated_at":"2024-07-02T16:34:26.575Z","phase":"Phase 2","brief_title":"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers","source_id_and_acronym":"NCT05919108","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 04/30/2030","primary_completion_date":" 04/30/2030","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2024-06-13"},{"id":"5281d885-db71-4720-b9bf-1c0b248f2e5b","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372614","created_at":"2022-05-13T12:54:23.489Z","updated_at":"2024-07-02T16:34:58.772Z","phase":"Phase 1","brief_title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","source_id_and_acronym":"NCT05372614 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4 • CASP3","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA","tags":["HER-2 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-06-05"},{"id":"12d6f8bf-b8cc-4e05-aaf9-f067a1855bd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01494662","created_at":"2021-01-18T06:15:41.454Z","updated_at":"2024-07-02T16:35:02.079Z","phase":"Phase 2","brief_title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","source_id_and_acronym":"NCT01494662","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-22"},{"id":"3a04215f-16bc-463d-a8c7-22a54bd276e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06109467","created_at":"2023-10-31T18:13:37.416Z","updated_at":"2024-07-02T16:35:06.096Z","phase":"Phase 2","brief_title":"Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer","source_id_and_acronym":"NCT06109467","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Nerlynx (neratinib) • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/12/2024","start_date":" 01/12/2024","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-05-03"},{"id":"b04da804-4c66-4d69-84c9-7b541be7c700","acronym":"","url":"https://clinicaltrials.gov/study/NCT03377387","created_at":"2021-01-18T16:40:04.269Z","updated_at":"2024-07-02T16:35:09.006Z","phase":"Phase 1/2","brief_title":"Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer","source_id_and_acronym":"NCT03377387","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"},{"id":"c5a4487c-936d-4c2d-b27e-f5b1144cbabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083662","created_at":"2023-10-16T16:13:44.248Z","updated_at":"2024-07-02T16:35:14.906Z","phase":"Phase 2","brief_title":"Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers","source_id_and_acronym":"NCT06083662","lead_sponsor":"Korea University Guro Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Herzuma (trastuzumab-pkrb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-03-13"},{"id":"346cfd98-eff6-4020-8d92-8bb29d1dd1e5","acronym":"FACT-2","url":"https://clinicaltrials.gov/study/NCT03812393","created_at":"2021-01-18T18:50:26.397Z","updated_at":"2024-07-02T16:35:25.920Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast","source_id_and_acronym":"NCT03812393 - FACT-2","lead_sponsor":"West Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/21/2019","start_date":" 06/21/2019","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2023-12-18"},{"id":"327d0ed8-e8d1-4d0f-9ef7-67bdf45498bd","acronym":"DIANER","url":"https://clinicaltrials.gov/study/NCT05252988","created_at":"2022-02-23T19:55:12.531Z","updated_at":"2024-07-02T16:35:26.111Z","phase":"Phase 2","brief_title":"Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib","source_id_and_acronym":"NCT05252988 - DIANER","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • loperamide"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/25/2025","primary_completion_date":" 03/25/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-12-15"},{"id":"7da24356-f31f-4c1a-9d80-3d2045e22819","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008275","created_at":"2023-08-23T15:11:13.833Z","updated_at":"2024-07-02T16:35:27.489Z","phase":"Phase 1","brief_title":"Neratinib in Combination With Ruxolitinib in Patients With mTNBC","source_id_and_acronym":"NCT06008275","lead_sponsor":"Baylor Research Institute","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Jakafi (ruxolitinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-30"},{"id":"fedc9e7d-89aa-4cee-acd2-a8ecd4f1e103","acronym":"","url":"https://clinicaltrials.gov/study/NCT03094052","created_at":"2021-01-18T15:14:38.972Z","updated_at":"2024-07-02T16:35:28.996Z","phase":"Phase 2","brief_title":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","source_id_and_acronym":"NCT03094052","lead_sponsor":"University of California, San Francisco","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • Mytesi (crofelemer) • loperamide"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 10/09/2018","start_date":" 10/09/2018","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-11-16"},{"id":"ed87f07f-d94b-4782-87e1-520859d6cee3","acronym":"GERTRUDE","url":"https://clinicaltrials.gov/study/NCT05933395","created_at":"2023-07-06T16:10:21.285Z","updated_at":"2024-07-02T16:35:31.527Z","phase":"Phase 2","brief_title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","source_id_and_acronym":"NCT05933395 - GERTRUDE","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4","pipe":"","alterations":" ","tags":["HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Nerlynx (neratinib) • Piqray (alpelisib) • Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2023-10-26"},{"id":"42f11aaa-f036-425b-b3a7-95ff30920135","acronym":"ELEANOR","url":"https://clinicaltrials.gov/study/NCT04388384","created_at":"2021-01-18T21:11:01.934Z","updated_at":"2024-07-02T16:35:31.929Z","phase":"","brief_title":"Real-life Pan-HER-blockade With Neratinib","source_id_and_acronym":"NCT04388384 - ELEANOR","lead_sponsor":"Pierre Fabre Pharma GmbH","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-24"},{"id":"06bce804-bede-4084-9f43-37dffac91812","acronym":"CVL009-2001","url":"https://clinicaltrials.gov/study/NCT06029816","created_at":"2023-09-08T20:10:17.441Z","updated_at":"2024-07-02T16:35:37.650Z","phase":"Phase 2","brief_title":"Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations","source_id_and_acronym":"NCT06029816 - CVL009-2001","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-09-08"},{"id":"533aa66c-4746-4431-98d9-b06b9456fac3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965064","created_at":"2021-07-16T13:53:19.296Z","updated_at":"2024-07-02T16:35:37.864Z","phase":"Phase 2","brief_title":"Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling","source_id_and_acronym":"NCT04965064","lead_sponsor":"University of Rochester","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-09-07"}]